Press release
OZ Biosciences announces a strategic partnership with ExploRNA Therapeutics to strengthen its mRNA platform with next-generation RNA capping technology
Strategic collaboration to develop innovative RNA cap analogs improving mRNA stability and translation efficiency.
Messenger RNA (mRNA) and self-amplifying RNA (saRNA) has emerged as a disruptive and highly promising therapeutic platform, enabling cells to produce any protein of interest. Through this collaboration, OZ Biosciences will integrate ExploRNA's proprietary ExploCapTM technology into its mRNA offering. ExploCapTM is a next-generation co-transcriptional capping reagent designed to generate high-quality capped mRNA with excellent biological properties.
High-quality RNA capping plays a central role in mRNA & saRNA performance, as it directly impacts:
• RNA quality,
• translation efficiency,
• degradation risk by skipping a production step
• downstream manufacturability.
ExploRNA's next-generation capping reagent ExploCapTM has been designed to flexibly fit various in vitro transcription (IVT) workflows providing reliable high-quality outcomes. ExploCapTM supports both unmodified and modified RNA, and provides a cost-effective alternative to industry-standard capping reagents.
OZ Biosciences brings strong expertise in mRNA and saRNA design, production and commercialization, together with the development and commercialization of proprietary lipid nanoparticle (LNP) formulations for nucleic acid delivery. Combined with ExploRNA's next-generation capping technologies, this partnership aims to deliver higher-performance mRNA products supporting research, bioproduction, and future therapeutic development programs."
"This partnership represents an important milestone in strengthening our RNA platform. Integrating ExploRNA's ExploCapTM technology into our RNA solutions allows us to further improve their quality and performance, supporting our customers as they advance RNA-based research and development programs." said Olivier Zelphati, CEO of OZ Biosciences.
Jacek Jemielity, CEO of ExploRNA Therapeutics, commented the deal saying "We are excited for OZ Biosciences to become our first partner in delivering high-quality mRNA created with our cap analogs to clients around the globe. We think this collaboration will help scientists researching and developing mRNA-based programs to easily access the benefits of next-generation capping solutions."
Both companies share a common ambition: to raise the standard of RNA tools available to biotech, pharmaceutical, and academic innovators worldwide, and to support the growing demand for robust, scalable, and high-performance mRNA technologies.
Further updates will follow as ExploCapTM-capped mRNA products are progressively integrated into the OZ Biosciences portfolio.
About OZ Biosciences
Founded in 2003 and headquartered in Marseille, France, OZ Biosciences creates, develops, and manufactures innovative molecular delivery systems for the worldwide scientific and pharmaceutical communities. The company's expertise spans from transfection to transduction technologies, RNA & LNP design and synthesis platforms, adjuvants and assay kits supporting applications ranging from research to cell and gene therapy development.
OZ Biosciences has built a strong portfolio of proprietary technologies, including lipid nanoparticles (LNPs), viral transduction enhancers, and GMP-oriented solutions.
For more information, please visit: https://ozbiosciences.com/
About ExploRNA Therapeutics
ExploRNA Therapeutics is a biotechnology company developing next-generation mRNA technologies, with a strong focus on advanced RNA capping solutions. The company designs proprietary cap analogs that enhance mRNA stability, translation efficiency, and protein expression-key parameters for high-performance mRNA-based applications. ExploRNA's technologies are compatible with standard in vitro transcription workflows and support the development of mRNA platforms and solutions for pharmaceutical and biotechnology partners.
For more information, please visit: https://explorna.com/
OZ Biosciences SAS
163 Avenue de Luminy, 13288, FRANCE
https://ozbiosciences.com/
contact@ozbiosciences.com
OZ Biosciences is a product development company that creates, develops and commercializes delivery systems of bioactive materials (DNA, siRNA, proteins, antibodies...), intended for the worldwide scientific community and pharmaceutical industries. Our mission is to assist scientists to accelerate the rhythm of discoveries by offering them technologically advanced tools such as transfection reagents and other life science research products. Principal innovations are based on proprietary technologies such as Magnetofection (magnetic-assisted transfection or infection), Magneto-Biolistic, transfection reagents, transduction tools, mRNA and lipids-based delivery systems (LNP). Specialized and expert in drug delivery systems, we also provide custom transfection, mRNA and LNP services and are involved in many international research projects.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OZ Biosciences announces a strategic partnership with ExploRNA Therapeutics to strengthen its mRNA platform with next-generation RNA capping technology here
News-ID: 4375800 • Views: …
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
